Be a Blood Donor
Subscribe to our eNewsletter
A First for Military Medicine: Platelet Additive Solutions
By Lt. Cmdr. Jonathan Hoiles, MSC, USN
Michael Harris (left), the first platelet additive solution-platelet donor at Naval Hospital Camp Lejeune enjoys a movie while Lab Technician Sean Anderson (right) operates the AMICUS separator.
The Blood Donor Center at Naval Hospital Camp Lejeune recently purchased its first apheresis collection device known as the AMICUS Separator—bringing a first to military medicine: platelet additive solutions. Instead of suspending platelets in 100 percent plasma, platelets are suspended in a mix of 65 percent platelet additive solution and 35 percent plasma. This solution, known as InterSol, is the only platelet additive solution approved by the Food and Drug Administration, and Naval Hospital Camp Lejeune is the first hospital in the Department of Defense to collect platelets in this way.
InterSol works so well because the solution contains naturally occurring constituents found in many cellular systems. Sodium acetate acts as a nutrient, sodium citrate prevents platelet clumping and activation, sodium phosphate buffers and sodium chloride is used for osmolarity.
The use of platelet additive solutions offers a number benefits improving patient safety while improving collection efficiency. With the reduced amount of plasma needed for platelet storage, more plasma is available for plasma products. This is especially important for Type AB donors. Group AB plasma is the universal plasma type and the demand for AB plasma is particularly high in the combat environment. Depending on the donor’s biological parameters, it is now possible to collect multiple platelet and plasma products during a single collection, thus improving product availability while also reducing recruiting and collecting costs.
A potential advantage to platelet additive solution-stored platelets is a reduction in the risk of reactions in the transfusion recipient. With a smaller plasma volume, platelet additive solution-stored platelets may reduce the risk of allergic reactions, ABO hemolytic reactions, and Transfusion Related Acute Lung Injury—a severe and sometimes fatal reaction thought to be linked to antibodies found in donor plasma. The decreased plasma volume in platelet additive solution-stored platelets will likely improve the overall safety of the platelet product.
“This is a great achievement for Navy Medicine and the Armed Services Blood Program,” says Cmdr. Roland Fahie, director of the Navy Blood Program. “This technology offers many benefits and is in line with Navy medicine’s goal to deliver the most beneficial and safest medical care to our beneficiaries.”
The team at the Naval Hospital Camp Lejeune Blood Donor Center is proud to be the first Armed Services Blood Program blood center to collect platelet additive solution-stored platelets. This new technology is an exciting advance in improving patient safety while enhancing collection efficiency, and is a leading example of the Armed Services Blood Program’s commitment to providing quality blood products for Service members and their families in both peace and war.
To learn more about InterSol and platelet additive solutions at the Naval Hospital Camp Lejeune, check out Page 4 of the February 2011 edition of
, the Naval Hospital Camp Lejeune’s command newspaper. View the article
To learn more about the Armed Services Blood Program or to make an appointment, visit us online:
. To interact directly with some of our staff or to get the latest news, visit us here:
Mission & Vision
Contact ASBP Office
Privacy & Security